Janux Therapeutics, Inc.
Company Stats
- Market Cap
- $1.1B
- as of Sep 30, 2026
- Shares Outstanding
- 61.1M
- Free Float
- 41.3%
Income Statement
- Revenue
- $10.0M
- Operating Income
- -$157.7M
- Net Income
- -$113.6M
- EBITDA
- -$155.6M
- Revenue Growth, 3Y
- 5.1%
- FCF Margin, 3Y Avg
- -632.9%
- FCF Margin, Worst Year
- -832.8%
Cash Flow
- Free Cash Flow
- -$83.3M
- FCF Yield
- -7.9%
- Owner FCF Yield
- -11.7%
Balance Sheet
- Cash & Equivalents
- $52.3M
Returns & Capital
- SBC, 3Y Avg
- $31.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $10.0M | -$83.3M | -832.8% |
| FY2024 | $10.6M | -$44.2M | -417.2% |
| FY2023 | $8.1M | -$52.4M | -648.6% |
| FY2022 | $8.6M | -$49.4M | -573.2% |
| FY2021 | $3.6M | -$18.5M | -507.5% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back